// App-Quantinova.ai

: Phase 2 Study of Blinatumomab in Japanese Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Researchers

Presenter

  • Yukio Kobayashi

Principal Investigators

  • Zachary F. Zimmerman

  • Iekuni Oh

  • Yoshinobu Maeda

  • Hironobu Minami

  • Toshihiro Miyamoto

  • Toru Sakura

  • Hiroatsu Iida

  • Yuqi Chen

  • Hitoshi Kiyoi

Medical Centers

  • Hematology Division, IUHW Mita Hospital, Tokyo, Japan

  • Global Development Oncology, Amgen Inc., Thousand Oaks, CA

  • Division of Hematology, Jichi Medical University, Tochigi, Japan

  • Department of Gastroenterology, Kanazawa University Hospital, Ishikawa, Japan

  • Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan

  • Department of Surgery and Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

  • Leukemia Research Center, Saiseikai Maebashi Hospital, Gunma, Japan

  • Department of Hematology, National Hospital Organization Nagoya Medical Center, Aichi, Japan

  • Amgen Inc, Thousand Oaks, CA

  • Department of Pathologic Oncology, Mie University Graduate School of Medicine, Mie, Japan

Locations

  • Japan

  • United States

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved